![Gregory Winter](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Gregory Winter
Fondateur chez BICYCLE THERAPEUTICS PLC
Fortune : 4 M $ au 31/05/2024
Profil
Gregory Winter is the founder of MedImmune Ltd.
(founded in 1989), Domantis Ltd.
(founded in 2000), and Bicycle Therapeutics Plc (founded in 2009).
He held the title of Non-Executive Director at each of these companies.
Currently, Mr. Winter holds the position of Non-Executive Director at Bit Bio Ltd., Director at BicycleTx Ltd.
(since 2017), Non-Executive Director at Immutrin Ltd., Fellow at The Royal Society, Trustee at The Kennedy Trust for Rheumatology Research, Advisor at Cambridge Innovation Capital Ltd, and Founding Partner at Ahren Innovation Capital LLP.
In the past, Mr. Winter served as Chairman at Biosceptre International Ltd.
(from 2016 to 2018), Deputy Director at UK Medical Research Council (from 1981 to 2012), Non-Executive Director at Biosceptre (Aust) Pty Ltd.
(from 2016 to 2018), and Member at The Medical Research Council.
Mr. Winter obtained his undergraduate degree in 1973 and his doctorate degree in 1976 from the University of Cambridge.
Détentions connues dans des sociétés publiques
Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
---|---|---|---|---|
08/04/2024 | 176 177 ( 0,46% ) | 4 M $ | 31/05/2024 |
Postes actifs de Gregory Winter
Sociétés | Poste | Début |
---|---|---|
BICYCLE THERAPEUTICS PLC | Fondateur | 01/01/2009 |
The Royal Society | Corporate Officer/Principal | - |
BicycleTx Ltd.
![]() BicycleTx Ltd. Miscellaneous Commercial ServicesCommercial Services Founded in 2017, part of Bicycle Therapeutics Plc, BicycleTx Ltd. provides business support services. The company is based in Babraham, UK. | Directeur/Membre du Conseil | 04/12/2017 |
Cambridge Innovation Capital Ltd
![]() Cambridge Innovation Capital Ltd Investment ManagersFinance Cambridge Innovation Capital Ltd (Cambridge Innovation Capital) is a venture capital firm founded in 2013. The firm is headquartered in Cambridge, United Kingdom. | Consultant / Advisor | - |
Ahren Innovation Capital LLP
![]() Ahren Innovation Capital LLP Investment ManagersFinance Ahren Innovation Capital LLP (Ahren) is a venture capital firm founded in 2017 by Alice Newcombe-Ellis. The firm is headquartered in Cambridge, UK. | Private Equity Investor | - |
The Kennedy Trust for Rheumatology Research
![]() The Kennedy Trust for Rheumatology Research Financial ConglomeratesFinance The Kennedy Trust for Rheumatology Research is a British research-focused company that was founded in 1969. The non-profit company is based in London, UK. The Kennedy Trust supports research into rheumatic and related musculoskeletal diseases. | Directeur/Membre du Conseil | - |
Bit Bio Ltd.
![]() Bit Bio Ltd. Miscellaneous Commercial ServicesCommercial Services Bit Bio Ltd. engages in research and experimental development on natural sciences and engineering. Its products are human-induced skeletal myocytes and glutamatergic neurons. The company was founded by Mark Kotter in 2016 and is headquartered in Cambridge, the United Kingdom. | Directeur/Membre du Conseil | - |
Anciens postes connus de Gregory Winter
Sociétés | Poste | Fin |
---|---|---|
Biosceptre (Aust) Pty Ltd.
![]() Biosceptre (Aust) Pty Ltd. Pharmaceuticals: MajorHealth Technology Biosceptre (Aust) Pty Ltd. develops and commercializes antibody technologies for applications in the diagnosis and treatment of cancer. The company was founded in 2000 and is headquartered in North Ryde, Australia. | Président | 20/12/2018 |
Biosceptre International Ltd.
![]() Biosceptre International Ltd. BiotechnologyHealth Technology Part of Biosceptre (Aust) Pty Ltd., Biosceptre International Ltd. is a biopharmaceutical company based in Babraham, UK. The British company is focused on developing their BRiDGECAR™ system, which combines nfP2X7-targeted technology with highly potent chimeric antigen receptor (CAR) T-cell therapy and multiple targeted antibodies. The company's researchers are pioneers in cancer therapeutic development, with a vision of targeted treatment for millions of cancer patients across the world. The company's multi-targeted BRiDGECAR™ system has the potential to benefit a range of malignancies and make a drastic difference to the lives of millions of cancer patients. The company's advisory board includes Sir Gregory Winter, a 2018 Nobel Prize winner in Chemistry. | Président | 01/01/2018 |
░░ ░░░░░░░ ░░░░░░░░ ░░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░░░ ░░░░ | ░░░░░░░░░ | - |
░░░ ░░░░░░░ ░░░░░░░░ ░░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - |
Formation de Gregory Winter
University of Cambridge | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Sociétés cotées | 1 |
---|---|
BICYCLE THERAPEUTICS PLC | Health Technology |
Entreprise privées | 12 |
---|---|
Domantis Ltd.
![]() Domantis Ltd. Pharmaceuticals: MajorHealth Technology Domantis Ltd. develops domain antibody therapeutics for treating highly unmet diseases. It enables DABS to serve as building blocks for therapeutics simultaneously directed at more than one disease target. The company was founded in December 2000 and is headquartered Middlesex, the United Kingdom. | Health Technology |
UK Medical Research Council | |
The Medical Research Council
![]() The Medical Research Council Miscellaneous Commercial ServicesCommercial Services The Medical Research Council provides human healthcare and social services. It offers funding for biomedical spectrum, fundamental lab-based science, clinical trials and all major disease areas. The company was founded in 1913 and is headquartered in Swindon, the United Kingdom. | Commercial Services |
The Royal Society | Miscellaneous |
Biosceptre International Ltd.
![]() Biosceptre International Ltd. BiotechnologyHealth Technology Part of Biosceptre (Aust) Pty Ltd., Biosceptre International Ltd. is a biopharmaceutical company based in Babraham, UK. The British company is focused on developing their BRiDGECAR™ system, which combines nfP2X7-targeted technology with highly potent chimeric antigen receptor (CAR) T-cell therapy and multiple targeted antibodies. The company's researchers are pioneers in cancer therapeutic development, with a vision of targeted treatment for millions of cancer patients across the world. The company's multi-targeted BRiDGECAR™ system has the potential to benefit a range of malignancies and make a drastic difference to the lives of millions of cancer patients. The company's advisory board includes Sir Gregory Winter, a 2018 Nobel Prize winner in Chemistry. | Health Technology |
MedImmune Ltd.
![]() MedImmune Ltd. BiotechnologyHealth Technology MedImmune Ltd. engages in research, development and exploitation of products in the field of molecular engineering. The company was founded on December 11, 1989 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
BicycleTx Ltd.
![]() BicycleTx Ltd. Miscellaneous Commercial ServicesCommercial Services Founded in 2017, part of Bicycle Therapeutics Plc, BicycleTx Ltd. provides business support services. The company is based in Babraham, UK. | Commercial Services |
Cambridge Innovation Capital Ltd
![]() Cambridge Innovation Capital Ltd Investment ManagersFinance Cambridge Innovation Capital Ltd (Cambridge Innovation Capital) is a venture capital firm founded in 2013. The firm is headquartered in Cambridge, United Kingdom. | Finance |
Ahren Innovation Capital LLP
![]() Ahren Innovation Capital LLP Investment ManagersFinance Ahren Innovation Capital LLP (Ahren) is a venture capital firm founded in 2017 by Alice Newcombe-Ellis. The firm is headquartered in Cambridge, UK. | Finance |
Biosceptre (Aust) Pty Ltd.
![]() Biosceptre (Aust) Pty Ltd. Pharmaceuticals: MajorHealth Technology Biosceptre (Aust) Pty Ltd. develops and commercializes antibody technologies for applications in the diagnosis and treatment of cancer. The company was founded in 2000 and is headquartered in North Ryde, Australia. | Health Technology |
The Kennedy Trust for Rheumatology Research
![]() The Kennedy Trust for Rheumatology Research Financial ConglomeratesFinance The Kennedy Trust for Rheumatology Research is a British research-focused company that was founded in 1969. The non-profit company is based in London, UK. The Kennedy Trust supports research into rheumatic and related musculoskeletal diseases. | Finance |
Bit Bio Ltd.
![]() Bit Bio Ltd. Miscellaneous Commercial ServicesCommercial Services Bit Bio Ltd. engages in research and experimental development on natural sciences and engineering. Its products are human-induced skeletal myocytes and glutamatergic neurons. The company was founded by Mark Kotter in 2016 and is headquartered in Cambridge, the United Kingdom. | Commercial Services |